MKI67 and cancer: In IBrC patients with Ki67 staining < 20%, we observed longer disease-free survival and overall survival as well, compared to IBrC patients with Ki67 staining > 20% (68.5 vs. 61 months for median DFS and 70 vs. 62.5 months for median OS), what brightly suggest that Ki67 expression > 20% contributes to a higher risk of cancer recurrence and specific death.